These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35749919)

  • 1. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States.
    Paschen-Wolff MM; Velasquez R; Aydinoglo N; Campbell ANC
    J Subst Abuse Treat; 2022 Sep; 140():108828. PubMed ID: 35749919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The State of the Research on Opioid Outcomes Among Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexuality- and Gender-Diverse Populations: A Scoping Review.
    Paschen-Wolff MM; Kidd JD; Paine EA
    LGBT Health; 2023 Jan; 10(1):1-17. PubMed ID: 36318023
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of availability of long-acting medication for opioid use disorder.
    Shover CL; Humphreys K
    Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences of and recommendations for LGBTQ+-affirming substance use services: an exploratory qualitative descriptive study with LGBTQ+ people who use opioids and other drugs.
    Paschen-Wolff MM; DeSousa A; Paine EA; Hughes TL; Campbell ANC
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):2. PubMed ID: 38172902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
    Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender disparities in opioid treatment progress in methadone versus counseling.
    Guerrero E; Amaro H; Kong Y; Khachikian T; Marsh JC
    Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):52. PubMed ID: 34162420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
    Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
    Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of Specific Programs and Medications for Addiction Treatment to Vulnerable Populations: Results from the Addiction Treatment Locator, Assessment, and Standards (ATLAS) Survey.
    Oldfield BJ; Chen K; Joudrey PJ; Biegacki ET; Fiellin DA
    J Addict Med; 2023 Jul-Aug 01; 17(4):477-480. PubMed ID: 37579115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a cascade of care for opioid use disorder among individuals in jail.
    Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
    J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
    Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
    Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
    Krawczyk N; Garrett B; Ahmad NJ; Patel E; Solomon K; Stuart EA; Saloner B
    Drug Alcohol Depend; 2021 Mar; 220():108512. PubMed ID: 33508692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.